$100.15
3.79% day before yesterday
Nasdaq, Aug 29, 10:10 pm CET

Lam Research Target price 2025 - Analyst rating & recommendation

Lam Research Classifications & Recommendation:

Buy
77%
Hold
23%

Lam Research Price Target

Target Price $117.30
Price $100.15
Potential 17.12%
Number of Estimates 32
32 Analysts have issued a price target Lam Research 2026 . The average Lam Research target price is $117.30. This is 17.12% higher than the current stock price. The highest price target is $141.75 41.54% , the lowest is $80.80 19.32% .
A rating was issued by 39 analysts: 30 Analysts recommend Lam Research to buy, 9 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Lam Research stock has an average upside potential 2026 of 17.12% . Most analysts recommend the Lam Research stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2030


Jun '25 2026
Estimates
Revenue Billion $ 18.44 20.31
23.68% 10.18%
EBITDA Margin 34.10% 33.47%
8.50% 1.86%
Net Margin 29.06% 28.46%
13.18% 2.08%

34 Analysts have issued a sales forecast Lam Research 2026 . The average Lam Research sales estimate is $20.3b . This is 10.18% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $21.6b 17.09% , the lowest is $18.1b 2.09% .

This results in the following potential growth metrics:

Revenue Estimates

2025 $18.4b 23.68%
2026 $20.3b 10.18%
2027 $22.3b 9.80%
2028 $24.0b 7.68%
2029 $27.1b 13.03%
2030 $27.2b 0.28%

21 Analysts have issued an Lam Research EBITDA forecast 2026. The average Lam Research EBITDA estimate is $6.8b . This is 8.12% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $7.5b 19.59% , the lowest is $5.2b 16.99% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $6.3b 34.19%
2026 $6.8b 8.12%
2027 $7.7b 13.18%
2028 $8.5b 10.61%
2029 $9.8b 15.70%
2030 $9.5b 3.73%

EBITDA Margin

2025 34.10% 8.50%
2026 33.47% 1.86%
2027 34.50% 3.08%
2028 35.43% 2.70%
2029 36.27% 2.37%
2030 34.82% 4.00%

34 Lam Research Analysts have issued a net profit forecast 2026. The average Lam Research net profit estimate is $5.8b . This is 7.90% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $6.4b 20.08% , the lowest is $5.0b 5.79% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $5.4b 39.98%
2026 $5.8b 7.90%
2027 $6.6b 13.98%
2028 $7.4b 12.71%
2029 $9.7b 31.01%

Net Margin

2025 29.06% 13.18%
2026 28.46% 2.08%
2027 29.55% 3.83%
2028 30.93% 4.67%
2029 35.85% 15.91%

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030


Jun '25 2026
Estimates
Earnings Per Share $ 4.15 4.56
43.10% 9.88%
P/E 21.98
EV/Sales 6.15

34 Analysts have issued a Lam Research forecast for earnings per share. The average Lam Research EPS is $4.56 . This is 8.83% higher than earnings per share in the financial year 2025. The highest EPS forecast is $5.07 21.00% , the lowest is $3.98 5.01% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $4.15 43.10%
2026 $4.56 9.88%
2027 $5.19 13.82%
2028 $5.85 12.72%
2029 $7.67 31.11%

P/E ratio

Current 23.90 18.20%
2026 21.98 8.04%
2027 19.28 12.28%
2028 17.11 11.26%
2029 13.06 23.67%

Based on analysts' sales estimates for 2026, the Lam Research stock is valued at an EV/Sales of 6.15 and an P/S ratio of 6.24 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.77 7.64%
2026 6.15 9.22%
2027 5.60 8.93%
2028 5.20 7.13%
2029 4.60 11.53%
2030 4.59 0.28%

P/S ratio

Current 6.88 6.88%
2026 6.24 9.24%
2027 5.68 8.93%
2028 5.28 7.13%
2029 4.67 11.53%
2030 4.66 0.28%

Current Lam Research Upgrades & Downgrades

Analyst Rating Action Date
Cantor Fitzgerald
Overweight
Overweight
Unchanged Aug 21 2025
Argus Research
Buy
Buy
Unchanged Aug 01 2025
Mizuho
Outperform
Outperform
Unchanged Aug 01 2025
Citigroup
Buy
Buy
Unchanged Aug 01 2025
Morgan Stanley
Equal-Weight
Equal-Weight
Unchanged Jul 31 2025
Oppenheimer
Outperform
Outperform
Unchanged Jul 31 2025
Needham
Buy
Buy
Unchanged Jul 31 2025
Analyst Rating Date
Unchanged
Cantor Fitzgerald:
Overweight
Overweight
Aug 21 2025
Unchanged
Argus Research:
Buy
Buy
Aug 01 2025
Unchanged
Mizuho:
Outperform
Outperform
Aug 01 2025
Unchanged
Citigroup:
Buy
Buy
Aug 01 2025
Unchanged
Morgan Stanley:
Equal-Weight
Equal-Weight
Jul 31 2025
Unchanged
Oppenheimer:
Outperform
Outperform
Jul 31 2025
Unchanged
Needham:
Buy
Buy
Jul 31 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today